Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Manifaxine
Clinical data | |
---|---|
Other names | GW-320,659 |
Routes of administration |
Oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H15F2NO2 |
Molar mass | 243.254 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Manifaxine (developmental code name GW-320,659) is a norepinephrine–dopamine reuptake inhibitor developed by GlaxoSmithKline through structural modification of radafaxine, an isomer of hydroxybupropion and one of the active metabolites of bupropion. Manifaxine was researched for treatment of attention deficit hyperactivity disorder (ADHD) and obesity and was found to be safe, reasonably effective, and well-tolerated for both applications. However, no results were reported following these initial trials and development was discontinued.
Synthesis
The Grignard reaction between 3,5-difluorobenzonitrile [64248-63-1] (1) and ethylmagnesium bromide gives 3,5-difluoropropiophenone [135306-45-5] (2). Halogenation with molecular bromine occurs at the alpha-keto position providing 2-bromo-3',5'-difluoropropiophenone [135306-46-6] (3). Intermolecular ring formation with DL-Alaninol (2-Aminopropanol) [6168-72-5] completed the synthesis of Manifaxine (4).